復星醫藥(02196.HK):BioNTech授權開發針對COVID-19疫苗產品
復星醫藥(02196.HK)(600196.SH)公布,美國東部時間3月13日,控股子公司復星醫藥產業與在美國納斯達克上市的德國公司BioNTech簽訂許可協議,BioNTech授權復星醫藥產業在區域內獨家開發、商業化基於其專有的mRNA技術平台研發的、針對COVID-19的疫苗產品。
復星醫藥產業將根據約定向BioNTech支付至多8,500萬美元的許可費,並在約定的銷售提成期間內按該產品年度毛利的35%支付銷售提成。
BioNTech已開發以脂質納米微粒(LNP)為傳遞系統的mRNA治療技術平台。mRNA疫苗是將攜帶遺傳信息的核酸分子導入人體,使得體內細胞產生相應抗原,從而誘導人體產生中和抗體並刺激T細胞應答,通過體液免疫及細胞免疫的雙重機制對抗病毒。與減毒疫苗不同,mRNA疫苗不具有與感染相關的風險,可以提高接種安全性。此外,由於mRNA疫苗通過無細胞體外轉錄過程生產,較傳統疫苗相對簡便和快捷,從而能夠更有效地應對疫情爆發情況下對疫苗產品的需求。
惟公告指出,該產品在德國尚處於臨床前研究階段;全球範圍內尚無基於mRNA技術平台研發的治療或預防性藥物/疫苗獲得上市批准。
同日,公司控股子公司復星實業與BioNTech簽訂《約束性條款書》。經協商,復星實業擬以每股31.63美元價格認購BioNTech新增發行約158.08萬股普通股,認購金額約5,000萬美元。預計目標股份約佔BioNTech經擴大後股份總數的0.7%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.